Abstract
Heart valve replacement, as a safe and effective treatment for severe valvular heart disease, can significantly improve hemodynamics in patients. However, such patients then require lifelong anticoagulant therapy. Warfarin, a cheap and highly effective vitamin K antagonist, remains the major anticoagulant recommended for lifelong use following mechanical heart valve replacement. However, the effect of warfarin anticoagulant therapy is complicated by physiological differences among patients and non-compliance with treatment at different degrees. Effective management of warfarin therapy after heart valve replacement is currently an important issue. Portable coagulometers and the emergence of the Internet have provided new opportunities for long-term management of anticoagulation therapy, but the safety and affordability of this approach remain to be fully evaluated. This paper reviews recent progress on the use of portable coagulometers and the Internet in the management of warfarin anticoagulation therapy following mechanical heart valve replacement, which offers opportunities for reducing complications during postoperative anticoagulation and for facilitating patient compliance during follow-up.
Introduction
Valvular heart disease, as the main cause of heart function disorder, reduces quality of life and can be fatal. Epidemiological surveys show that the incidence of valvular heart disease is gradually increasing as the global population ages (1–3), and it has attracted heightened concern in the practice of cardiac surgery and medicine. Unlike other major cardiovascular diseases such as atrial fibrillation, valvular disease as an organic disease of the heart lacks effective drug therapy. Since the beginning of this century, interventional therapy has developed rapidly and demonstrated potential advantages for treatment of some high-risk valvular diseases. However, for patients with valvular diseases for whom intervention is indicated, open-heart surgery is still the standard approach.
Heart valve replacement, as a safe and effective clinical treatment, can significantly improve cardiac hemodynamics and quality of life (4). In terms of the choice of replacement valve, various options exist because of the different material properties of mechanical biological valves. Studies have shown that the risk of bleeding is about one-third less in patients with a biological valve than with a mechanical valve, although the risk of repeat surgery is more than three times higher (4, 5). Therefore, the current consensus is that mechanical valves are more suitable for younger patients. Interaction between artificial materials and blood can easily lead to thrombosis on the valve surface, which can cause stroke and even death in severe cases. Clinical guidelines recommend that patients undergoing mechanical heart valve replacement take anticoagulant drugs for life (5–8).
Warfarin is a highly effective and inexpensive vitamin K antagonist that is widely used for preventing blood clot formation in artificial joint replacements, venous thromboembolism, atrial fibrillation and heart valve surgery. However, the therapeutic window for warfarin is narrow, and significant differences exist among individuals in its effect on blood coagulation. Patient genotype, gender, age, education, and compliance with clinical follow-up can affect the warfarin efficacy to varying degrees (9, 10). Studies have shown that increasing the frequency of anticoagulant index measurements is helpful for improving the efficacy of oral anticoagulants and reducing the occurrence of bleeding, thromboembolism, and other complications (11, 12). Traditional management of anticoagulant outpatient services is cumbersome. Patients have to go through outpatient registration and have blood drawn for a hospital or off-site laboratory to obtain coagulation indices, such as the international normalized ratio (INR). Finally, the outpatient doctor or pharmacist determines an INR target value and prescribes a dose adjustment plan. With these complicated procedures and long patient-waiting times, regular patient monitoring has become challenging.
Development of point-of-care (POC) INR determination by bedside real-time portable coagulometers has revolutionized management of warfarin anticoagulant therapy, allowing patients to self-test and self-manage their anticoagulant therapy conveniently. In recent years, the popularization and rapid development of the Internet have provided new opportunities for clinical anticoagulation monitoring and post-discharge follow-up (12–14). In this review, we summarize the latest research on warfarin anticoagulant therapy that takes advantage of new developments in Internet technology and self-testing. This review has three sections. First, we review management of anticoagulation-based on fixed network terminals. Second, we discuss progress in anticoagulation management based on mobile terminals and focus on several large clinical trials conducted in China. Finally, we analyze problems that stand in the way of further development of portable coagulometers connected to the Internet for managing anticoagulation therapy after cardiac valvular disease. Our discussion is intended to provide inspiration for improved postoperative follow-up management and to reduce anticoagulation complications.
Summary of the warfarin anticoagulant self-management model
Point-of-care testing (POCT) allows for testing physiological specimens, such as fingertip (venous) blood, collected using portable analytical instruments to facilitate access to results in a short period of time. Currently, the INR is the main detection index describing anticoagulation. Mainstream anticoagulant instruments are based on electrochemical or physical principles (including optics, acoustics, and electrical properties) and make use of a paper test card (15). Currently, instrument manufacturers, such as Roche, have made portable coagulometers commercially available on a large scale. Compared to the large instruments used in hospitals and laboratories for testing blood, portable coagulometers are easy to operate, require less time and space, allow for more frequent testing, and significantly improve patient quality of life.
Measurements of blood coagulation based on electrochemical principles
An electrode and a dry reagent are placed on a test card in advance. Upon interaction between the blood and paper, oxidation of thrombin by the substance in the reagent occurs, generating an electric current. The INR of the blood sample is calculated based on changes in current (16, 17).
Measurements based on optical principles
Coagulation changes the optical properties of blood, and the INR of coagulation is calculated by measuring its viscoelasticity and refractive index. Therefore, instruments contain a light source and optical detector. For Cascade POC (Helena Laboratories Point of Care, USA), the test card contains magnetic iron oxide particles and other reagents. An electromagnetic field causes the iron oxide particles in the reagents to move, which causes fluctuations in the optical transmittance of the fluid. Blood entering the card triggers coagulation process, which reduces movement of the iron particles and thereby stabilizes the transmittance signal, upon which the instrument calculates the corresponding INR (18).
Measurements based on acoustic principles and optical detection
The approach is similar to that described above. Blood coagulation changes the basic acoustic state of the liquid, and by observing changes in the resonant frequency of the blood, changes in its viscosity can be analyzed and the time course of coagulation time can be obtained. Effective acoustic measurement devices include quartz crystal mass (QCM) balance resonators and surface acoustic waves (19). A portable coagulation detection method based on a QCM sensor has been proposed that allows researchers to obtain dissipative factor results and coagulation indicators via smartphone analysis. And it was proved that the test was as accurate as conventional methods based on large machines (19).
Measurements based on electrical principles
The resistance of a liquid is closely related to its composition. Clotting is a complex physiological process. A series of changes in clotting factors eventually lead to fibrin aggregation and coagulation, thus changing the electrical resistance of blood. Coagulation can be monitored indirectly by detecting the rate of change of blood resistance over time. A microfluidic test platform with screen-printed electrodes and a fully integrated single-chip impedance analyzer has been developed by Chen (20). In this design, constant frequency voltage excitation is provided, and the differential impedance signal is recorded to calculate the coagulation time.
These different design principles do not lead to large differences in the effectiveness of clinical testing. Patients and medical staff can choose according to clinical needs, economic resources, and requirements of medical insurance policies. Current mainstream portable clotting devices include CoaguChekXS (Roche), ProTime (ITC), INRatio (Hemosense), and Harmony (Johnson / Johnson) (21–26) (Table 1).
Table 1
| Device | CoaguChek S Roche Diagnostics GMBH | CoaguChek XS Roche Diagnostics GMBH | CoaguChek XS Plus Roche Diagnostics GMBH | ProTime 3 International Technidyne Corp | INRatio Hemosense Inc. |
|---|---|---|---|---|---|
| Target group | Patient or professional use | Patient or professional use | Professional use only | Patient or professional use | Patient or professional use |
| Approximate cost of monitor (USD) | n/a | 499 | 1,499 | 1,800 | 600 |
| Approximate cost of test strips/cuvettes (USD) | 6 test strips: 50.25 24 the test strips: 200.88 | 6 test strips: 50.25 24 the test strips: 200.88 | 6 test strips: 50.25 24 the test strips: 200.88 | Box of 25 cuvettes: The 145.00 | 12 test strips: 80.00 48 test strips: 298.00 |
| Blood sample | 10 μl of whole blood (venous or capillary) | 10 μl of whole blood (venous or capillary) | 10 μl of whole blood (venous or capillary) | 27 μl of whole blood (venous or capillary) | 15 μl of whole blood (capillary only) |
| Detection principle | Iron oxide | Electrochemical | Electrochemical | Optical clot detection | Electrochemical |
| Memory store | 60 tests with time and data | 100 tests with time and date | 500 tests with patient details, time, and date | 30 tests with time, date, and quality control results | 60 tests with time, date, and quality control results |
| Quality control | Liquid quality control | Strip integrity check | Liquid, strip integrity check | Internal (2 levels) and liquid | Internal (2 levels) only |
Characteristics of point-of-care INR devices licensed for use in Canada*.
The main attraction of portable clotting machines is that they require less time to test the blood when compared with traditional testing methods that involve large machines. Studies have shown that hospital testing laboratory requires 65.02 ± 24.5 min to test INR, whereas portable coagulation tests require only about 1–4 min (27, 28). The design principles of mainstream portable blood coagulation instruments do not differ greatly, and product upgrades focus mainly on improving convenience and user comfort.
“Self-management” in patients receiving warfarin anticoagulant therapy refers to patients monitoring their INR at home using a portable coagulometer and adjusting the dose of warfarin by consulting treatment guidelines or a clinician. Studies have shown that self-management of anticoagulant therapy in the early postoperative period can improve initiation of medication and detection of blood clotting, maintain INR in a lower range, reduce the occurrence of complications such as severe bleeding and thromboembolism, and have significant pharmacoeconomic advantages (29, 30). Gallagher et al. (31) reported that when patients switched to INR self-monitoring and online management, short-term costs were significantly higher than those of outpatient anticoagulation management, with a difference of about €60 between the two groups over a 6-month period. This is mainly because current devices are expensive and health insurance policies do not completely cover the costs.
Most researchers believe that the use of Internet technology combined with self-testing INR can reduce adverse events in anticoagulation therapy. If warfarin-related adverse events are included in the medical costs, the new management model may be more economical in the long run, especially for patients whose homes are far from the clinic (32–34). One study (35) revealed that, compared with routine care, self-monitoring saved 1,187 GBP per person over the past 10 years. More than 112 million GBP could be saved if 10% of the current 950,000 patients switched to portable devices within 10 years.
In the following section, we primarily focus on how portable blood coagulation instruments can be effectively used with the Internet and different terminals for economical and effective warfarin therapy following heart valve replacement.
“Internet +” applied to warfarin anticoagulation management in patients after heart valve replacement
“Internet+Medical”
“Internet + medical” refers to the application of Internet technology to traditional medical fields. Researchers initially attempted to integrate the Internet with the medical field to expand education on diseases, diagnosis, and treatment, and to outpatient follow-ups. This application did not only provide a reliable and convenient means for individuals to obtain information about health and disease control and prevention but also for patients to access help from medical institutions (36, 37). It also improved clinical practice by making it more convenient and personalized. At present, the “Internet + medical” model is basically stable, including doctor-patient entities and online diagnosis and treatment systems and databases. Doctor-patient entities include doctors, nurses, pharmacies, clinics and patients. Online diagnosis and treatment systems mainly include online registration, consultation systems, electronic medical records and settlement and evaluation systems. Databases are generally individual or public. Individual databases contain all tests, examination results and medical records of patients, and are only accessible to doctors, nurses and patients to facilitate diagnosis and treatment. Public databases contain anonymized patient information that has often been processed in various ways and which allow limited access to medical personnel, researchers, patients, social enterprises and government regulatory agencies. Therefore, Internet-based anticoagulation management should adhere to the requirements of offline entities and online procedures, as shown in Figure 1.
Figure 1
Model of warfarin anticoagulation therapy combining Internet and INR self-testing.
Computer-based fixed communication and self-management of anticoagulation
Computer-based fixed communication refers to that in which customers connect to computers or network equipment mainly through fixed lines, such as cables and optical cables. It is characterized by fixed connection lines and immobility or limited mobility of network terminals. Therefore, this mode mainly existed in the early development of the Internet and currently in underdeveloped countries or regions. With the development of mobile Internet and artificial intelligence, the drawbacks of this model have become apparent. The invention of the portable coagulometer allowed patients to monitor INR at home and self-administer warfarin according to the test results, which addressed the problem of outpatient anticoagulation therapy. Initial attempts by researchers to have patients test their own INR and consult their doctors on medications resulted in significantly improved patient satisfaction (38–41). However, telephone communication is not always timely; it is difficult to analyze statistically and has other disadvantages. With the popularity of personal computers in foreign countries, clinicians began to try to follow up patients by e-mail, which to a certain extent solved the difficult problem of preservation of patient data. Due to the difficulty in performing professional data analysis by e-mail, researchers later set up professional anticoagulation management websites for guiding patient self-testing of INR at home. This hybrid approach has become a new direction in research on management of anticoagulation therapy, and a number of remote home anticoagulation management systems have emerged.
Finkelstein et al. (42) reported in 2003 that a home automated telemanagement (HAT) system provided multidisciplinary support for patients receiving anticoagulant therapy and improved patient compliance to treatment plan. The system consists of a home unit, a HAT server, and a clinician unit. Patients connect to a coagulation-time detector using a home computer, and their symptoms and test results are automatically sent to the server and analyzed by the system. This was an early demonstration of an Internet-based medical expert system. This patient-server-physician system design was later incorporated into remote anticoagulation management systems. Koertke et al. (43) analyzed data from 1,571 patients who received mechanical valves from January 2006 to April 2012; 1,304 patients underwent aortic valve replacement, whereas 189 and 78 patients underwent mitral valve replacement and double valve replacement, respectively. The patients were randomly assigned to one of three groups: low dose INR self-management (LOW), very low-dose (VLO)INR once, or twice (VLT) weekly testing. Over a period of 2 years, the proportions of patients in the LOW, VLO, and VLT groups without bleeding were 96.3%, 98.6%, and 99.1%, respectively (P = 0.008). The corresponding values for thrombotic events were 99.0%, 99.8%, and 98.9%. This study suggests that remotely managed ultra-low-dose INR self-management is comparable to low-dose INR in terms of thrombosis risk and superior in terms of controlling bleeding risk.
We analyzed time in therapeutic range (TTR) outcomes from eight major studies and found that INR self-testing combined with online management could improve TTR (31, 44–51) (Table 2). Additionally, effective patient education has influenced warfarin treatment of valvular heart disease (52). In addition to designing the doctor-patient communication website, other researchers (53) have developed Internet courses to help educate patients about the importance of adhering to a medication regimen, thereby improving their health and reducing thromboembolic events and hospitalizations. With the rapid development of mobile Internet in this century, online management based on websites and e-mail has gradually turned to mobile phones and other mobile terminals, providing additional options for remote warfarin management.
Table 2
| Research | Intervention group | Control group | P value | ||
|---|---|---|---|---|---|
| Mean | SD | Mean | SD | ||
| Ryan et al. (31, 44) | 72 | 19.7 | 59 | 13.5 | <0.05 |
| Verret et al. (45) | 80 | 13.5 | 75.5 | 24.7 | 0.79 |
| Soliman et al. (46) | 72.9 | 11 | 53.9 | 14 | 0.01 |
| David et al. (47) | 66.2 | 14.2 | 62.4 | 17.1 | <0.001 |
| Khan et al. (48) | 71.1 | 14.5 | 63.2 | 25.9 | >0.05 |
| Brasen et al. (49) | 82.7 | 12.0 | 81.6 | 15.8 | 0.31 |
| Cao et al. (50) | 74.0 | 30.8 | 78.9 | 17.7 | 0.393 |
| Cao et al. (51) | 79.35 | 26.31 | 52.38 | 12.67 | <0.001 |
TTR value comparison using warfarin between online and hospital management*.
Mobile Internet and anticoagulant self-managing
Mobile Internet technology removes the requirement that a user's physical connection to the network should be at a specific location (54, 55). The widespread use of smartphones and tablets has allowed online voice calls, text messaging, and third-party apps (APPs) to profoundly change lifestyles. In 2021, the number of internet users worldwide was 4.9 billion, up from 4.6 billion in the previous year (56). Substantial evidence suggested that voice contact and SMS interventions can improve cardiovascular preventive care in developed countries by monitoring factors, such as patients' weight, smoking status, and physical activity (53–55). Over the past decade, new social media sites have been developed, providing opportunities for doctors and patients to interact virtually and share written information, graphic displays, videos, photos, and other forms of communication (57). At present, several patients and medical personnel are able to access and exchange health and medical information through mobile networks. This form of communication provides an opportunity to disseminate health guidance at low cost and may increase the cost-effectiveness of health interventions. Additionally, it can promote social support and influence health behavior (58, 59).
Therefore, the mobile Internet provides more options for anticoagulation management. Patients can access applications through mobile phones, tablets and other terminals to manage drug dose, which can not only improve the frequency of anticoagulation monitoring, but also enable patients to arrange more rapid and efficient return visits without increasing treatment risk, save time and economic cost, and improve quality of life and treatment satisfaction.
Yamamura et al. (60) used a drug therapy support system, CoaguChek, to test INRs, and patients could upload the data to the system at any time using their mobile phones. In the event of abnormal data, the attending clinician conferred with the pharmacist to determine a new warfarin dose and inform the patient via e-mail. This initiative was a significant improvement over fixed communications because mobile terminals remove spatial limitations on communication between patients and medical staff. Further, a novel Anticlot Assistant smartphone application has been developed by Li (61), which will provide valuable data for related research. Zhu (62) conducted a prospective, multicenter, randomized, open-label, controlled clinical trial with 1-year follow-up that incorporated a mobile medical network application. Their APP was divided mainly into doctor and patient modules. The doctor could contact the patient in real-time, answer the patient's questions, educate the patient, and guide treatment. As in most studies, the Internet-based group showed a significantly higher TTR, and anticoagulation complications, including bleeding and embolic events, were less frequent in the Internet-based group than in the conventional group (6.94% vs. 12.74%; P = 0.01). Jiang et al. (63) developed an APP named “Yixing”, which was not connected to a portable clotting instrument. Compared with follow-up using telephone remote management, this APP established a communication platform for patients and pharmacists, facilitating timely management of warfarin, improving efficiency, and increasing fraction of TTR (FTTR). However, not all studies have reported advantages of the new anticoagulation management model (33, 47).
If significant benefits in terms of increasing TTR or reducing hospitalization and mortality rates cannot be demonstrated, then anticoagulation after heart valve surgery will continue to be a problem for clinicians (64). In a recent study of 383 patients who underwent mechanical heart valve surgery, no significant differences in TTR existed between self-testing combined with the Internet and clinical anticoagulation management (65), which is in contrary to findings from most previous studies. In another recent study (51), the incidence of extreme INR values was significantly lower in patients treated via the specialized anticoagulant software “Alfalfa” than in those treated using conventional warfarin management. However, compared with the control management group, patients using Alfalfa had a higher incidence of minor bleeding events, which was attributed to the opportunity for users to more frequently report treatment complications. Patients who are routinely followed up are often questioned over a longer period of time; therefore, they may forget about minor adverse events. Therefore, large-scale and long-term studies are still needed to investigate whether the anticoagulation management model based on self-testing and Internet connectivity is really superior to traditional outpatient management (Table 3).
Table 3
| Adverse events | Major bleeding events | Minor bleeding events | Total bleeding | Thromboem-bolic events | Hospitalization | Mortality | |
|---|---|---|---|---|---|---|---|
| Ryan et al. (31, 44) | Intervention group | - | - | 0 | 2 | - | - |
| Control group | - | - | 1 | 1 | - | - | |
| Verret et al. (45) | Intervention group | 2 | 24 | 26 | 0 | 9 | 0 |
| Control group | 1 | 22 | 23 | 0 | 6 | 0 | |
| Soliman et al. (46) | Intervention group | 1 | - | 1 | 0 | - | 1 |
| Control group | 1 | - | 1 | 1 | - | 1 | |
| Cao et al. (50) | Intervention group | 1 | 8 | 9 | 0 | 1 | - |
| Control group | 0 | 7 | 7 | 0 | 0 | - | |
| Cao et al. (51) | Intervention group | 2 | 45 | 47 | 1 | 1 | - |
| Control group | 12 | 20 | 32 | 1 | 12 | - | |
Comparisons of adverse events using warfarin under online vs. hospital management*.
Chinese researchers have used QQ social media software to follow up patients undergoing mechanical heart valve replacement. The results show that social media software can yield good follow-up results, and the advantages of QQ communication are greater for patients living in rural or remote areas (66). Chen et al. (67) conducted a non-randomized prospective controlled clinical study. One hundred patients were divided into groups undergoing cardiac valve replacement (40 cases), self-monitoring (40 cases), and self-management (20 cases). A portable blood clot device (CoaguChek Xs) was used for INR self-monitoring, and WeChat instant messaging software was used for communications during follow-up. The TTRs of the three groups were 45.9%, 61.2%, and 65.4%, respectively, and the FTTRs were 48.3%, 60.7%, and 64.9%. The instant messaging software platforms, “WeChat” and “WhatsApp”, have a large number of users and have affected traditional doctor-patient communications by facilitating the safety of patients' anticoagulation treatments, and to some extent alleviating the burden on medical personnel. There is still a lack of large-scale research on anticoagulation management that combines portable coagulometers with social media around the world. Instant messaging tools and social media place low demands on the educational level of patients, but cannot provide for professional statistical analysis of clinical data. Given the limitations of using WeChat, WhatsApp, Facebook, and other social media software to perform anticoagulation follow-up management and help educate patients and their families about cardiac surgery, development of professional anticoagulation management procedures seems inevitable (68–70).
Problems and limitations
Both professionalism and universality should be emphasized
Common social media software has a wide audience but lacks medical expertise. It is only convenient for communication between doctors and patients but cannot individualize medical treatment. Additionally, a complex, overly specialized medical device or application can limit patient compliance. Therefore, design of portable coagulation instruments and anticoagulation management procedures should follow the principles of simplicity, convenience and ease of learning. The majority of patients undergoing heart valve replacement are elderly, who have low learning ability and are slow to absorb new information. Complex and cumbersome detectors or applications will reduce the number of eligible patients and reliability of the resulting statistical data.
Medical devices and clinical models should always be patient-centered
The rights of patients should always be a primary consideration. Consideration of ethical issues in emerging models can help ensure that doctors provide medical services more safely (71). Although self-management of warfarin anticoagulation therapy can significantly reduce monetary cost and enhance clinical benefits, complications, such as bleeding and thrombosis, should not be ignored. Whether using a clotting device or accessing Internet software, medical staff and product designers must consider the timely, effective and appropriate treatment to patients with clinical complications or extreme events. There is no doubt that such intellectual and legal questions are of great importance.
Cost considerations cannot be ignored
The market price of a Xprecia Stride Coagulation Meter (Siemens Healthcare) is approximately US$ 1428, and the Roche CoaguChek XS Pro Meter costs up to US$ 2,14. As a result, portable clotting machines have been slow to achieve wide use because of their high cost. Moreover, professional anticoagulation management applications are costly to develop and slow to produce a monetary return. Therefore, the relevant studies based on POCT coagulation detectors are only conducted in some large heart centers or hospitals, and studies on their connection with the Internet or mobile terminals, such as smart phones, are rarely reported. There is reason to believe that there will be many such studies during the “Internet plus healthcare” boom, including attempts to include the cost of portable clotting tests in health insurance.
Cyber security
When patients and doctors use the “Internet +” anticoagulation management model, protecting patients' medical privacy is an essential consideration. As a general rule, patient medical records should not be made known to anyone other than the patient and the attending physician, which is basic privacy protection. However, anonymized patient medical data can be aggregated into public research databases. When patient data is used for medical or policy research, patients should be informed and their data handled according to their wishes. Finally, some national security data must be protected from leaks and attacks.
Test times and frequency of doctor-patient communication
Although multiple tests can effectively monitor blood coagulation, excessive coagulation testing can undoubtedly increase the time, effort and cost for patients with stable INR levels. Being able to connect online at any time and place can also add to doctors' workload outside of their regular hours. Approaches to achieving a favorable balance between reducing the burden on medical staff and ensuring safety and low cost for patients merits further research.
What can we expect?
Warfarin, as the most common anticoagulant, is widely used in clinical practice. The rapid development of new technology and ideas has resulted in increased opportunities for warfarin anticoagulation therapy.
To ensure accurate results, next generation coagulation detectors will need to further reduce costs and use new materials and production processes. Related products will need to be more convenient and accurate. Presently, some portable coagulation instruments have Bluetooth, networking, and other functions that allow automatic uploading of test results and alerts in the event of a critical test value. Therefore, future efforts are expected to focus on approaches to ensuring the accuracy of test results and therefore patient safety, and may even lead to non-invasive methods for detection of clotting indicators and artificial intelligence to provide medical care (72).
The Internet has been widely used in the field of medicine. At present, it focuses on two general directions: discovering potential medical clues and guiding personalized treatment. Patients test themselves and upload their INR data, and doctors view patient anticoagulation records at different times and places to comprehensively evaluate patient health status. By careful analysis and evaluation, individual differences in the effects of warfarin and lifestyle, food and other events on anticoagulation stability can be assessed. Widespread adoption of the Internet and self-test INR anticoagulation management model, along with constantly improved databases, can lead to vast amounts of data. This will include warfarin anticoagulation data from different countries and nationalities and ultimately necessitate cloud computing and big data analysis to guide clinical practice.
The use of properly equipped medical apps and tools on smartphones and other mobile devices can reduce the need for specialist care, resulting in significant cost savings for the healthcare system, and “on demand” communication will further promote a harmonious doctor-patient relationship. At the same time, it should be possible to develop a portable blood detector by integrating coagulation index detection with other blood indicators such as blood sugar and biochemical indicators. The anti-coagulation management terminal based on the “Internet +” concept has developed into a chronic disease management platform, which is the direction of future research. In some developing countries, patients in remote areas with large rural populations cannot enjoy the convenience of anticoagulation services in large central hospitals. The Internet + self-monitoring of anticoagulation model has become even more urgent during the COVID-19 pandemic as city closures and population quarantines have resulted in the failure of many patients to receive clinical anticoagulation therapy after mechanical valve replacement, thus increasing the risk of thromboembolic complications such as bleeding. In conclusion, this new model of anticoagulation management is worth pursuing, and there is good reason to expect that it will bring benefits to heart valve replacement patients, clinicians, and the community healthcare system as a whole.
Conclusion
INR self-monitoring based on portable coagulation instruments and doctor-patient communication based on Internet technology offer many clinical and economic advantages over traditional anticoagulation management schemes for patients following valve replacement. This approach is especially valuable in areas with underdeveloped transportation systems where outpatient visits can be challenging. Legal and cost issues relevant to its development should be considered. Therefore, prospective, multi-center, large-sample clinical studies are warranted to validate this model.
Statements
Author contributions
YH wrote and revised the article. LH and ZH guided and structured the content of the article. All authors contributed to the article and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1.
CoffeySRoberts-ThomsonRBrownACarapetisJChenMEnriquez-SaranoMet alGlobal epidemiology of valvular heart disease. Nat Rev Cardiol. (2021) 18:853–64. 10.1038/s41569-021-00570-z
2.
YangYWangZChenZWangXZhangLLiSet alCurrent status and etiology of valvular heart disease in China: a population-based survey. BMC Cardiovasc Disord. (2021) 21:339. 10.1186/s12872-021-02154-8
3.
DomenechBPomarJLPrat-GonzálezSVidalBLópez-SotoACastellaMet alValvular heart disease epidemics. J Heart Valve Dis. (2016) 25:1–7.
4.
NishimuraRAOttoCMBonowROCarabelloBAErwinJP3rdFleisherLAet al2017AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. (2017) 135:e1159–95. 10.1161/CIR.0000000000000503
5.
ZhangHDongYAoXZhuDDongL. Optimal oral anticoagulant therapy in Chinese patients with mechanical heart valves. Eur J Pharm Sci. (2020) 144:105202. 10.1016/j.ejps.2019.105202
6.
MakkarRRFontanaGJilaihawiHChakravartyTKofoedKFDe BackerOet alPossible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med. (2015) 373:2015–24. 10.1056/NEJMoa1509233
7.
WolbergASRosendaalFRWeitzJIJafferIHAgnelliGBaglinTet alVenous thrombosis. Nat Rev Dis Primers. (2015) 1:15006. 10.1038/nrdp.2015.6
8.
KiyoseATSuzumuraEALaranjeiraLBuehlerAMSantoJAEBerwangerOet alComparison of biological and mechanical prostheses for heart valve surgery: a systematic review of randomized controlled trials. Arq Bras Cardiol. (2019) 112:292–301. 10.5935/abc.20180272
9.
WangXXuBLiangHJiangSTanHWangXet alDistribution characteristics and factors influencing oral warfarin adherence in patients after heart valve replacement. Patient Prefer Adherence. (2018) 12:1641–8. 10.2147/PPA.S172223
10.
LiBLiuRWangCRenCZhangSZhangFet alImpact of genetic and clinical factors on warfarin therapy in patients early after heart valve replacement surgery. Eur J Clin Pharmacol. (2019) 75:1685–93. 10.1007/s00228-019-02747-5
11.
MatcharDBLoveSRJacobsonAKEdsonRUyedaLPhibbsCSet alThe impact of frequency of patient self-testing of prothrombin time on time in target range within VA cooperative study #481: the home INR study (THINRS), a randomized, controlled trial. J Thromb Thrombolysis. (2015) 40:17–25. 10.1007/s11239-014-1128-8
12.
HeneghanCWardAPereraR, Self-Monitoring; Trialist Collaboration, BankheadCFullerAStevensRet alSelf-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet. (2012) 379:322–34. 10.1016/S0140-6736(11)61294-4
13.
XiaXWuJZhangJ. The effect of online versus hospital warfarin management on patient outcomes: a systematic review and meta-analysis. Int J Clin Pharm. (2018) 40:1420–9. 10.1007/s11096-018-0731-8
14.
Menéndez-JándulaBGarcía-ErceJAZazoCLarrad-MurL. Long-term effectiveness and safety of self-management of oral anticoagulants in real-world settings. BMC Cardiovasc Disord. (2019) 19:186. 10.1186/s12872-019-1168-2
15.
SahaABajpaiAKrishnaVBhattacharyaS. Evolving paradigm of prothrombin time diagnostics with its growing clinical relevance towards cardio-compromised and COVID-19 affected population. Sensors. (2021) 21:2636. 10.3390/s21082636
16.
MartinCL. i-STAT—combining chemistry and haematology in PoCT. Clin Biochem Rev. (2010) 31:81–4.
17.
BarcellonaDFenuLMarongiuF. Point-of-care testing INR: an overview. Clin Chem Lab Med. (2017) 55:800–5. 10.1515/cclm-2016-0381
18.
Helena laboratories, pont of care, Cascade® POC analyzer. Available at:https://www.helena.com/Operator%20Manuals/Cascade%20POC%20Op%20Man%20D6500099D.pdf
19.
YaoJFengBZhangZLiCZhangWGuoZet alBlood coagulation testing smartphone platform using quartz crystal microbalance dissipation method. Sensors. (2018) 18:3073. 10.3390/s18093073
20.
ChenSHLuYCYenCY. Electrochemical blood test strips and diagnosis systems using the same. U.S. Patent No 9,000,770. (2015).
21.
ConnockMStevensCFry-SmithAJowettSFitzmauriceDMooreDet alClinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. Health Technol Assess. (2007) 11:iii-iv, ix-66. 10.3310/hta11380
22.
Health Canada. Medical devices active license listing. Available at:http://www.hc-sc.gc.ca/dhp-mps/md-im/licen/mdlic-eng.php
23.
BrownAWellsPJaffeyJMcGahanLPoonM-CCimonKet alPoint-of-care monitoring devices for long-term oral anticoagulation therapy: clinical and cost effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2007 Technology Report No 72.
24.
NHS Purchasing and Supply Agency. Buyers’ guide: point of care coagulometers for monitoring oral anticoagulation. CEP 07026. Centre for evidence-based purchasing, London (2008).
25.
Medical Advisory Secretariat. Point-of-care international normalized ratio (INR) monitoring devices for patients on long-term oral anticoagulation therapy: an evidence-based analysis. Ont Health Technol Assess Ser. (2009) 9:1–114.
26.
da Silva SaraivaSOrsiFASantosMPMachadoTMontalvãoSCosta-LimaCet alHome management of INR in the public health system: feasibility of self-management of oral anticoagulation and long-term performance of individual POC devices in determining INR. J Thromb Thrombolysis. (2016) 42:146–53. 10.1007/s11239-016-1335-6
27.
RattanabannakitCNilanontYKomoltriCPrayoonwiwatNPoungvarinN. Accuracy and clinical utility of a portable coagulometer in an emergency setting. J Med Assoc Thai. (2011) 94(Suppl 1):S89–93.
28.
SmithMHarrisonDRipleyTGraceSBronzeMSJacksonR. Warfarin management using point-of-care testing in a university-based internal medicine resident clinic. Am J Med Sci. (2012) 344:289–93. 10.1097/MAJ.0b013e318245f93c
29.
KoertkeHMinamiKBoethigDBreymannTSeifertDWagnerOet alINR self-management permits lower anticoagulation levels after mechanical heart valve replacement. Circulation. (2003) 108:II75–8. 10.1161/01.cir.0000089185.80318.3f
30.
KoertkeHZittermannATenderichGWagnerOEl-ArousyMKrianAet alLow-dose oral anticoagulation in patients with mechanical heart valve prostheses: final report from the early self-management anticoagulation trial II. Eur Heart J. (2007) 28:2479–84. 10.1093/eurheartj/ehm391
31.
GallagherJMc CarthySWoodsNRyanFO’SheaSByrneS. Economic evaluation of a randomized controlled trial of pharmacist-supervized patient self-testing of warfarin therapy. J Clin Pharm Ther. (2015) 40:14–9. 10.1111/jcpt.12215
32.
WhiteHDGruberMFeyziJKaatzSTseHFHustedSet alComparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med. (2007) 167:239–45. 10.1001/archinte.167.3.239
33.
ChenQLDongLDongYJZhaoSLFuBWangYQet alSecurity and cost comparison of INR self-testing and conventional hospital INR testing in patients with mechanical heart valve replacement. J Cardiothorac Surg. (2015) 10:4. 10.1186/s13019-015-0205-1
34.
KantitoSSaokaewSYamwongSVathesatogkitPKatekaoWSritaraPet alCost-effectiveness analysis of patient self-testing therapy of oral anticoagulation. J Thromb Thrombolysis. (2018) 45:281–90. 10.1007/s11239-017-1588-8
35.
CraigJAChaplinSJenksM. Warfarin monitoring economic evaluation of point of care self-monitoring compared to clinic settings. J Med Econ. (2014) 17:184–90. 10.3111/13696998.2013.877468
36.
DemirisGAfrinLBSpeedieSCourtneyKLSondhiMVimarlundVet alPatient-centered applications: use of information technology to promote disease management and wellness. A white paper by the AMIA knowledge in motion working group. J Am Med Inform Assoc. (2008) 15:8–13. 10.1197/jamia.M2492
37.
Bujnowska-FedakMMWaligóraJMastalerz-MigasA. The internet as a source of health information and services. Adv Exp Med Biol. (2019) 1211:1–16. 10.1007/5584_2019_396
38.
JeonHRParkJS. Development and application of a self-management program based on prothrombin INR monitoring for patients with cardiac valve replacement. J Korean Acad Nurs. (2015) 45:554–64. 10.4040/jkan.2015.45.4.554
39.
CryderBTFelczakMADarkwaAPatelHJanociakJDRihaniR. Transition of stable patients from traditional anticoagulation clinic services to telephonic management. Int J Clin Pharm. (2017) 39:569–72. 10.1007/s11096-017-0428-4
40.
ThompsonJLBurkhartHMDalyRCDearaniJAJoyceLDSuriRMet alAnticoagulation early after mechanical valve replacement: improved management with patient self-testing. J Thorac Cardiovasc Surg. (2013) 146:599–604. 10.1016/j.jtcvs.2012.03.088
41.
AlhmoudENAbd El SamadOBElewaHAlkhozondarOSoalyEEl AnanyR. Drive-up INR testing and phone-based consultations service during COVID-19 pandemic in a pharmacist-lead anticoagulation clinic in Qatar: monitoring, clinical, resource utilization, and patient-oriented outcomes. J Am Coll Clin Pharm. (2021) 4:1117–25. 10.1002/jac5.1469
42.
FinkelsteinJKhareRAnsellJ. Feasibility and patients’ acceptance of home automated telemanagement of oral anticoagulation therapy. AMIA Annu Symp Proc. (2003) 2003:230–4.
43.
KoertkeHZittermannAWagnerOSecerS, Christ of Huth, SciangulaAet alTelemedicine-guided, very low-dose international normalized ratio self-control in patients with mechanical heart valve implants. Eur Heart J. (2015) 36:1297–305. 10.1093/eurheartj/ehu330
44.
RyanFByrneSO’SheaS. Randomized controlled trial of supervised patient self-testing of warfarin therapy using an internet-based expert system. J Thromb Haemost. (2009) 7:1284–90. 10.1111/j.1538-7836.2009.03497.x
45.
VerretLCouturierJRozonASaudrais-JanecekSSt-OngeANguyenAet alImpact of a pharmacist-led warfarin self-management program on quality of life and anticoagulation control: a randomized trial. Pharmacotherapy. (2012) 32:871–9. 10.1002/j.1875-9114.2012.01116
46.
Soliman HamadMAvan EekelenEvan AgtTvan StratenAH. Self-management program improves anticoagulation control and quality of life: a prospective randomized study. Eur J Cardiothorac Surg. (2009) 35:265–9. 10.1016/j.ejcts.2008.10.020
47.
MatcharDBJacobsonADolorREdsonRUyedaLPhibbsCSet alEffect of home testing of international normalized ratio on clinical events. N Engl J Med. (2010) 363:1608–20. 10.1056/NEJMoa1002617
48.
KhanTIKamaliFKestevenPAveryPWynneH. The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation. Br J Haematol. (2004) 126:557–64. 10.1111/j.1365-2141.2004.05074.x
49.
BrasenCLMadsenJSParknerTBrandslundI. Home management of warfarin treatment through a real-time supervised telemedicine solution: a randomized controlled trial. Telemed J E Health. (2019) 25:109–15. 10.1089/tmj.2017.0260
50.
CaoHWuJZhangJ. Outcomes of warfarin therapy managed by pharmacists via hospital anticoagulation clinic versus online anticoagulation clinic. Int J Clin Pharm. (2018) 40:1072–7. 10.1007/s11096-018-0674-0
51.
CaoHJiangSLvMWuTChenWZhangJ. Effectiveness of the alfalfa app in warfarin therapy management for patients undergoing venous thrombosis prevention and treatment: cohort study. JMIR Mhealth Uhealth. (2021) 9:e23332. 10.2196/23332
52.
ZandiSImaniBGholamrezaS. Self-care training and informational support of patients with a mechanical heart valve on the international normalized ratio and bleeding complications. Kardiochir Torakochirurgia Pol. (2021) 18:80–6. 10.5114/kitp.2021.107468
53.
Talboom-KampEPWAVerdijkNAKasteleynMJHarmansLMTalboomIJSHNumansMEet alEffect of a combined education and eHealth programme on the control of oral anticoagulation patients (PORTALS study): a parallel cohort design in Dutch primary care. BMJ Open. (2017) 7:e017909. 10.1136/bmjopen-2017-017909
54.
Pfaeffli DaleLWhittakerRJiangYStewartRRollestonAMaddisonR. Text message and internet support for coronary heart disease self-management: results from the Text4Heart randomized controlled trial. J Med Internet Res. (2015) 17:e237. 10.2196/jmir.4944
55.
PietteJDListJRanaGKTownsendWStriplinDHeislerM. Mobile health devices as tools for worldwide cardiovascular risk reduction and disease management. Circulation. (2015) 132:2012–27. 10.1161/CIRCULATIONAHA.114.008723
56.
Global number of internet users 2005-2021, Published by Statista Research Department, Jul 27, 2022. Available at:https://www.statista.com/statistics/273018/number-of-internet-users-worldwide/.
57.
LeungRGuoHPanX. Social media users’ perception of telemedicine and mHealth in China: exploratory study. JMIR Mhealth Uhealth. (2018) 6:e181. 10.2196/mhealth.7623
58.
DorjeTZhaoGTsoKWangJChenYTsokeyLet alSmartphone and social media-based cardiac rehabilitation and secondary prevention in China (SMART-CR/SP): a parallel-group, single-blind, randomised controlled trial. Lancet Digit Health. (2019) 1:e363–74. 10.1016/S2589-7500(19)30151-7
59.
MasoniMGuelfiMR. Whatsapp and other messaging apps in medicine: opportunities and risks. Intern Emerg Med. (2020) 15:171–3. 10.1007/s11739-020-02292-5
60.
YamamuraKYanoKHirookaYHirashikiAMuroharaTYamadaK. A successful case of a patient undergoing warfarin and S-1 therapy using internet-based control of home-measured PT-INR. Yakugaku Zasshi. (2015) 135:925–7. 10.1248/yakushi.15-00016
61.
LiYDongLXiangDZhangYChenXLongJet alPatient compliance with an anticoagulation management system based on a smartphone application. J Thromb Thrombolysis. (2019) 48:263–9. 10.1007/s11239-019-01859-0
62.
ZhuZLiCShenJWuKLiYLiuKet alNew internet-based warfarin anticoagulation management approach after mechanical heart valve replacement: prospective, multicenter, randomized controlled trial. J Med Internet Res. (2021) 23:e29529. 10.2196/29529
63.
JiangSHeQYanJZhaoLZhengYChenPet alEvaluation of a pharmacist-led remote warfarin management model using a smartphone application (yixing) in improving patients’ knowledge and outcomes of anticoagulation therapy. Front Pharmacol. (2021) 12:677943. 10.3389/fphar.2021.677943
64.
YanagawaBWhitlockRPVermaSGershBJ. Anticoagulation for prosthetic heart valves. Curr Opin Cardiol. (2016) 31:176–82. 10.1097/HCO.0000000000000259
65.
van ZylMWysokinskiWEJaegerTMCasanegraAIGershBJMcBaneRD2nd. In-home compared with in-clinic warfarin therapy monitoring in mechanical heart valves: a population-based study. Mayo Clin Proc Innov Qual Outcomes. (2020) 4:511–20. 10.1016/j.mayocpiqo.2020.05.003
66.
ZhangJLiuMChenQWuJCaoH. Outcomes of an online pharmacist-managed anticoagulation clinic for individuals on warfarin therapy living in rural communities. Thromb Res. (2017) 157:136–8. 10.1016/j.thromres.2017.07.016
67.
ChenQLDongLShiYKZhaoSLChenH. Self-management of anticoagulation monitoring after mechanical heart valve replacement in a non-randomized controlled study. Chinese J Thoracic Cardiovascular Surg. (2016) 23:646–52.
68.
XiaXFuJWuTChenWJinhuaZ. Comparison of the outcomes of warfarin therapy and economics by online and offline anticoagulation management models: protocol for a randomised controlled trial. BMJ Open. (2019) 9:e031730. 10.1136/bmjopen-2019-031730
69.
ObamiroKOChalmersLLeeKBereznickiBJBereznickiLRE. Anticoagulation knowledge in patients with atrial fibrillation: an Australian survey. Int J Clin Pract. (2018) 72:e13072. 10.1111/ijcp.13072
70.
GuZCHuangSRDongLZhouQWangJFuBet alAn adapted neural-fuzzy inference system model using preprocessed balance data to improve the predictive accuracy of warfarin maintenance dosing in patients after heart valve replacement. Cardiovasc Drugs Ther. (2022) 36:879–89. 10.1007/s10557-021-07191-1
71.
LangarizadehMMoghbeliFAliabadiA. Application of ethics for providing telemedicine services and information technology. Med Arch. (2017) 71:351–5. 10.5455/medarh.2017.71.351-355
72.
BarrettMBoyneJBrandtsJBrunner-La RoccaHPDe MaesschalckLDe WitKet alArtificial intelligence supported patient self-care in chronic heart failure: a paradigm shift from reactive to predictive, preventive and personalised care. EPMA J. (2019) 10:445–64. 10.1007/s13167-019-00188-9
Summary
Keywords
mechanical valve replacement, Internet, warfarin, self-management, review
Citation
Huang Y, Huang L and Han Z (2022) Combining portable coagulometers with the Internet: A new model of warfarin anticoagulation in patients following mechanical heart valve replacement. Front. Surg. 9:1016278. doi: 10.3389/fsurg.2022.1016278
Received
10 August 2022
Accepted
26 September 2022
Published
12 October 2022
Volume
9 - 2022
Edited by
Robert Jeenchen Chen, Stanford University, United States
Reviewed by
Antonino S. Rubino, University of Campania Luigi Vanvitelli, Italy Maruti Haranal, U N Mehta Institute of Cardiology and Research, India
Updates
Copyright
© 2022 Huang, Huang and Han.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Zhen Han 2498159698@qq.com
Specialty Section: This article was submitted to Heart Surgery, a section of the journal Frontiers in Surgery
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.